Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients

Skin Cancer

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

Eur J Cancer

Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob JJ, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R

doi: 10.1016/j.ejca.2024.115161

Lung, Respiratory and Thoracic Cancer

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Oncologist

Skoulidis F, Li BT, Hochmair M, Govindan R, Vincent M, van der Wekken AJ, Reguart Aransay N, O'Byrne KJ, Girard N, Griesinger F, Nishio M, Häfliger S, Lindsay C, Reinmuth N, Paulus A, Papakotoulas P, Kim SW, Ferreira CG, Pasello G, Duruisseaux M, Gennatas S, Dimou A, Mehta B, Kormany W, Nduka C, Sylvester BE, Ardito-Abraham C, Wang Y, de Langen AJ

doi: 10.1093/oncolo/oyae356

Breast Cancer

Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials

Int J Cancer

Menz BD, Modi ND, Abuhelwa AY, Kuderer NM, Lyman GH, Swain SM, Kichenadasse G, Shahnam A, Haseloff M, Vitry A, Rammant E, Ramsey I, Chan RJ, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM

doi: 10.1002/ijc.70020

Skin Cancer

Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres

Eur J Cancer

van der Kooij MK, Kapiteijn E, Rutkowski P, Baurain JF, de Koning L, Speetjens FM, Bartoszek P, Rogala P, Cornélis F, Dudzisz-Śledź M, Rodrigues M, Piperno-Neumann S

doi: 10.1016/j.ejca.2025.115634

Skin Cancer

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

Eur J Cancer

Jurlander RS, Guldbrandt LM, Holmstroem RB, Madsen K, Donia M, Haslund CA, Schmidt H, Bastholt L, Ruhlmann CH, Svane IM, Ellebaek E

doi: 10.1016/j.ejca.2024.115053

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Lung, Respiratory and Thoracic Cancer

Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials

J Clin Oncol

Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AC

doi: 10.1200/JCO-24-01579

SPECIAL REPORT

Breast Cancer

Managing Side Effects in Breast Cancer Treatment

Breast Cancer

Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer

J Natl Compr Canc Netw

Park C, Liu YS, Kenawy AS, Lin YH, Liu Y, Heo JH

doi: 10.6004/jnccn.2025.7001

Related content

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials

Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials

Managing Side Effects in Breast Cancer Treatment

Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer